Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Autoantibodies as diagnostic markers and potential drivers of inflammation in ulcerative colitis.

Jodeleit H, Milchram L, Soldo R, Beikircher G, Schönthaler S, Al-Amodi O, Wolf E, Beigel F, Weinhäusel A, Siebeck M, Gropp R.

PLoS One. 2020 Feb 12;15(2):e0228615. doi: 10.1371/journal.pone.0228615. eCollection 2020.

2.

The Combination of Patient Profiling and Preclinical Studies in a Mouse Model Based on NOD/Scid IL2Rγ null Mice Reconstituted With Peripheral Blood Mononuclear Cells From Patients With Ulcerative Colitis May Lead to Stratification of Patients for Treatment With Adalimumab.

Jodeleit H, Caesar J, Villarroel Aguilera C, Sterz S, Holdt L, Beigel F, Stallhofer J, Breiteneicher S, Bartnik E, Siebeck M, Gropp R.

Inflamm Bowel Dis. 2019 Nov 29. pii: izz284. doi: 10.1093/ibd/izz284. [Epub ahead of print]

PMID:
31782956
3.

[Gastrointestinal side effects of apremilast : Characterization and management].

Pinter A, Beigel F, Körber A, Homey B, Beissert S, Gerdes S, Staubach-Renz P, Radtke MA, Mössner R.

Hautarzt. 2019 May;70(5):354-362. doi: 10.1007/s00105-019-4396-6. Review. German.

PMID:
30937481
4.

Targeting ulcerative colitis by suppressing glucose uptake with ritonavir.

Jodeleit H, Al-Amodi O, Caesar J, Villarroel Aguilera C, Holdt L, Gropp R, Beigel F, Siebeck M.

Dis Model Mech. 2018 Nov 21;11(11). pii: dmm036210. doi: 10.1242/dmm.036210.

5.

CD1a-Expressing Monocytes as Mediators of Inflammation in Ulcerative Colitis.

Al-Amodi O, Jodeleit H, Beigel F, Wolf E, Siebeck M, Gropp R.

Inflamm Bowel Dis. 2018 May 17. doi: 10.1093/ibd/izy073. [Epub ahead of print]

6.

Design and validation of a disease network of inflammatory processes in the NSG-UC mouse model.

Jodeleit H, Palamides P, Beigel F, Mueller T, Wolf E, Siebeck M, Gropp R.

J Transl Med. 2017 Dec 28;15(1):265. doi: 10.1186/s12967-017-1368-4.

7.

Immunological profiling of patients with ulcerative colitis leads to identification of two inflammatory conditions and CD1a as a disease marker.

Föhlinger M, Palamides P, Mansmann U, Beigel F, Siebeck M, Gropp R.

J Transl Med. 2016 Nov 3;14(1):310.

8.

A mouse model for ulcerative colitis based on NOD-scid IL2R γnull mice reconstituted with peripheral blood mononuclear cells from affected individuals.

Palamides P, Jodeleit H, Föhlinger M, Beigel F, Herbach N, Mueller T, Wolf E, Siebeck M, Gropp R.

Dis Model Mech. 2016 Sep 1;9(9):985-97. doi: 10.1242/dmm.025452. Epub 2016 Aug 4.

9.

Solid Organ Transplantation in Patients with Inflammatory Bowel Diseases (IBD): Analysis of Transplantation Outcome and IBD Activity in a Large Single Center Cohort.

Schnitzler F, Friedrich M, Stallhofer J, Schönermarck U, Fischereder M, Habicht A, Karbalai N, Wolf C, Angelberger M, Olszak T, Beigel F, Tillack C, Göke B, Zachoval R, Denk G, Guba M, Rust C, Grüner N, Brand S.

PLoS One. 2015 Aug 19;10(8):e0135807. doi: 10.1371/journal.pone.0135807. eCollection 2015.

10.

Lipocalin-2 Is a Disease Activity Marker in Inflammatory Bowel Disease Regulated by IL-17A, IL-22, and TNF-α and Modulated by IL23R Genotype Status.

Stallhofer J, Friedrich M, Konrad-Zerna A, Wetzke M, Lohse P, Glas J, Tillack-Schreiber C, Schnitzler F, Beigel F, Brand S.

Inflamm Bowel Dis. 2015 Oct;21(10):2327-40. doi: 10.1097/MIB.0000000000000515.

PMID:
26263469
11.

The NOD2 Single Nucleotide Polymorphism rs72796353 (IVS4+10 A>C) Is a Predictor for Perianal Fistulas in Patients with Crohn's Disease in the Absence of Other NOD2 Mutations.

Schnitzler F, Friedrich M, Wolf C, Stallhofer J, Angelberger M, Diegelmann J, Olszak T, Tillack C, Beigel F, Göke B, Glas J, Lohse P, Brand S.

PLoS One. 2015 Jul 6;10(7):e0116044. doi: 10.1371/journal.pone.0116044. eCollection 2015.

12.

The NOD2 p.Leu1007fsX1008 mutation (rs2066847) is a stronger predictor of the clinical course of Crohn's disease than the FOXO3A intron variant rs12212067.

Schnitzler F, Friedrich M, Wolf C, Angelberger M, Diegelmann J, Olszak T, Beigel F, Tillack C, Stallhofer J, Göke B, Glas J, Lohse P, Brand S.

PLoS One. 2014 Nov 3;9(11):e108503. doi: 10.1371/journal.pone.0108503. eCollection 2014.

13.
14.

Colesevelam for the treatment of bile acid malabsorption-associated diarrhea in patients with Crohn's disease: a randomized, double-blind, placebo-controlled study.

Beigel F, Teich N, Howaldt S, Lammert F, Maul J, Breiteneicher S, Rust C, Göke B, Brand S, Ochsenkühn T.

J Crohns Colitis. 2014 Nov;8(11):1471-9. doi: 10.1016/j.crohns.2014.05.009. Epub 2014 Jun 19.

PMID:
24953836
15.

Rate and predictors of mucosal healing in patients with inflammatory bowel disease treated with anti-TNF-alpha antibodies.

Beigel F, Deml M, Schnitzler F, Breiteneicher S, Göke B, Ochsenkühn T, Brand S.

PLoS One. 2014 Jun 16;9(6):e99293. doi: 10.1371/journal.pone.0099293. eCollection 2014.

16.

Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.

Kotlyar DS, Lewis JD, Beaugerie L, Tierney A, Brensinger CM, Gisbert JP, Loftus EV Jr, Peyrin-Biroulet L, Blonski WC, Van Domselaar M, Chaparro M, Sandilya S, Bewtra M, Beigel F, Biancone L, Lichtenstein GR.

Clin Gastroenterol Hepatol. 2015 May;13(5):847-58.e4; quiz e48-50. doi: 10.1016/j.cgh.2014.05.015. Epub 2014 May 28.

PMID:
24879926
17.

Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies.

Beigel F, Steinborn A, Schnitzler F, Tillack C, Breiteneicher S, John JM, Van Steen K, Laubender RP, Göke B, Seiderer J, Brand S, Ochsenkühn T.

Pharmacoepidemiol Drug Saf. 2014 Jul;23(7):735-44. doi: 10.1002/pds.3621. Epub 2014 Apr 30.

PMID:
24788825
18.

Oncostatin M mediates STAT3-dependent intestinal epithelial restitution via increased cell proliferation, decreased apoptosis and upregulation of SERPIN family members.

Beigel F, Friedrich M, Probst C, Sotlar K, Göke B, Diegelmann J, Brand S.

PLoS One. 2014 Apr 7;9(4):e93498. doi: 10.1371/journal.pone.0093498. eCollection 2014.

19.

Bile acid malabsorption assessed by 7 alpha-hydroxy-4-cholesten-3-one in pediatric inflammatory bowel disease: correlation to clinical and laboratory findings.

Gothe F, Beigel F, Rust C, Hajji M, Koletzko S, Freudenberg F.

J Crohns Colitis. 2014 Sep;8(9):1072-8. doi: 10.1016/j.crohns.2014.02.027. Epub 2014 Mar 22.

PMID:
24666974
20.

Serum 7-alpha-hydroxy-4-cholesten-3-one as a marker for bile acid loss in children.

Freudenberg F, Gothe F, Beigel F, Rust C, Koletzko S.

J Pediatr. 2013 Nov;163(5):1367-71.e1. doi: 10.1016/j.jpeds.2013.06.083. Epub 2013 Aug 20.

PMID:
23968740
21.

Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment.

Tillack C, Ehmann LM, Friedrich M, Laubender RP, Papay P, Vogelsang H, Stallhofer J, Beigel F, Bedynek A, Wetzke M, Maier H, Koburger M, Wagner J, Glas J, Diegelmann J, Koglin S, Dombrowski Y, Schauber J, Wollenberg A, Brand S.

Gut. 2014 Apr;63(4):567-77. doi: 10.1136/gutjnl-2012-302853. Epub 2013 Mar 6.

PMID:
23468464
22.

IRGM variants and susceptibility to inflammatory bowel disease in the German population.

Glas J, Seiderer J, Bues S, Stallhofer J, Fries C, Olszak T, Tsekeri E, Wetzke M, Beigel F, Steib C, Friedrich M, Göke B, Diegelmann J, Czamara D, Brand S.

PLoS One. 2013;8(1):e54338. doi: 10.1371/journal.pone.0054338. Epub 2013 Jan 24.

23.

Analysis of IL12B gene variants in inflammatory bowel disease.

Glas J, Seiderer J, Wagner J, Olszak T, Fries C, Tillack C, Friedrich M, Beigel F, Stallhofer J, Steib C, Wetzke M, Göke B, Ochsenkühn T, Diegelmann J, Czamara D, Brand S.

PLoS One. 2012;7(3):e34349. doi: 10.1371/journal.pone.0034349. Epub 2012 Mar 30.

24.

PTPN2 gene variants are associated with susceptibility to both Crohn's disease and ulcerative colitis supporting a common genetic disease background.

Glas J, Wagner J, Seiderer J, Olszak T, Wetzke M, Beigel F, Tillack C, Stallhofer J, Friedrich M, Steib C, Göke B, Ochsenkühn T, Karbalai N, Diegelmann J, Czamara D, Brand S.

PLoS One. 2012;7(3):e33682. doi: 10.1371/journal.pone.0033682. Epub 2012 Mar 21.

25.

The role of osteopontin (OPN/SPP1) haplotypes in the susceptibility to Crohn's disease.

Glas J, Seiderer J, Bayrle C, Wetzke M, Fries C, Tillack C, Olszak T, Beigel F, Steib C, Friedrich M, Diegelmann J, Czamara D, Brand S.

PLoS One. 2011;6(12):e29309. doi: 10.1371/journal.pone.0029309. Epub 2011 Dec 29.

26.

Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease.

Beigel F, Löhr B, Laubender RP, Tillack C, Schnitzler F, Breiteneicher S, Weidinger M, Göke B, Seiderer J, Ochsenkühn T, Brand S.

Digestion. 2012;85(1):47-54. doi: 10.1159/000333091. Epub 2011 Dec 14.

PMID:
22179489
27.

Infliximab does not affect postoperative complication rates in Crohn's patients undergoing abdominal surgery.

Kasparek MS, Bruckmeier A, Beigel F, Müller MH, Brand S, Mansmann U, Jauch KW, Ochsenkühn T, Kreis ME.

Inflamm Bowel Dis. 2012 Jul;18(7):1207-13. doi: 10.1002/ibd.21860. Epub 2011 Sep 16.

PMID:
21928373
28.

Pregnane X receptor (PXR/NR1I2) gene haplotypes modulate susceptibility to inflammatory bowel disease.

Glas J, Seiderer J, Fischer D, Tengler B, Pfennig S, Wetzke M, Beigel F, Olszak T, Weidinger M, Göke B, Ochsenkühn T, Folwaczny M, Müller-Myhsok B, Diegelmann J, Czamara D, Brand S.

Inflamm Bowel Dis. 2011 Sep;17(9):1917-24. doi: 10.1002/ibd.21562. Epub 2010 Dec 3.

PMID:
21830270
29.

CEACAM6 gene variants in inflammatory bowel disease.

Glas J, Seiderer J, Fries C, Tillack C, Pfennig S, Weidinger M, Beigel F, Olszak T, Lass U, Göke B, Ochsenkühn T, Wolf C, Lohse P, Müller-Myhsok B, Diegelmann J, Czamara D, Brand S.

PLoS One. 2011 Apr 29;6(4):e19319. doi: 10.1371/journal.pone.0019319.

30.

The NOD2 single nucleotide polymorphisms rs2066843 and rs2076756 are novel and common Crohn's disease susceptibility gene variants.

Glas J, Seiderer J, Tillack C, Pfennig S, Beigel F, Jürgens M, Olszak T, Laubender RP, Weidinger M, Müller-Myhsok B, Göke B, Ochsenkühn T, Lohse P, Diegelmann J, Czamara D, Brand S.

PLoS One. 2010 Dec 30;5(12):e14466. doi: 10.1371/journal.pone.0014466.

31.

Comparative analysis of the lambda-interferons IL-28A and IL-29 regarding their transcriptome and their antiviral properties against hepatitis C virus.

Diegelmann J, Beigel F, Zitzmann K, Kaul A, Göke B, Auernhammer CJ, Bartenschlager R, Diepolder HM, Brand S.

PLoS One. 2010 Dec 8;5(12):e15200. doi: 10.1371/journal.pone.0015200.

32.

Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-α antibody-treated patients with inflammatory bowel disease.

Beigel F, Schnitzler F, Paul Laubender R, Pfennig S, Weidinger M, Göke B, Seiderer J, Ochsenkühn T, Brand S.

Inflamm Bowel Dis. 2011 Jan;17(1):91-8. doi: 10.1002/ibd.21362.

PMID:
20564536
33.

Evidence for STAT4 as a common autoimmune gene: rs7574865 is associated with colonic Crohn's disease and early disease onset.

Glas J, Seiderer J, Nagy M, Fries C, Beigel F, Weidinger M, Pfennig S, Klein W, Epplen JT, Lohse P, Folwaczny M, Göke B, Ochsenkühn T, Diegelmann J, Müller-Myhsok B, Roeske D, Brand S.

PLoS One. 2010 Apr 29;5(4):e10373. doi: 10.1371/journal.pone.0010373.

34.

Oesophageal ulceration after selective internal radiation therapy in a patient with carcinoma of unknown primary.

Kubisch CH, Beigel F, Ihrler S, Goke B, Reiser MF, Hoffmann RT.

Z Gastroenterol. 2010 May;48(5):546-50. doi: 10.1055/s-0028-1109694. Epub 2009 Dec 2.

PMID:
20449787
35.

The presence of fistulas and NOD2 homozygosity strongly predict intestinal stenosis in Crohn's disease independent of the IL23R genotype.

Jürgens M, Brand S, Laubender RP, Seiderer J, Glas J, Wetzke M, Wagner J, Pfennig S, Tillack C, Beigel F, Weidinger M, Schnitzler F, Kreis ME, Göke B, Lohse P, Herrmann K, Ochsenkühn T.

J Gastroenterol. 2010 Jul;45(7):721-31. doi: 10.1007/s00535-010-0231-7. Epub 2010 Apr 29.

PMID:
20428899
36.

Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis.

Jürgens M, Laubender RP, Hartl F, Weidinger M, Seiderer J, Wagner J, Wetzke M, Beigel F, Pfennig S, Stallhofer J, Schnitzler F, Tillack C, Lohse P, Göke B, Glas J, Ochsenkühn T, Brand S.

Am J Gastroenterol. 2010 Aug;105(8):1811-9. doi: 10.1038/ajg.2010.95. Epub 2010 Mar 2.

PMID:
20197757
37.

Safety of adalimumab in Crohn's disease during pregnancy: case report and review of the literature.

Jürgens M, Brand S, Filik L, Hübener C, Hasbargen U, Beigel F, Tillack C, Göke B, Ochsenkühn T, Seiderer J.

Inflamm Bowel Dis. 2010 Oct;16(10):1634-6. doi: 10.1002/ibd.21198. No abstract available.

PMID:
20027647
38.

Hepatosplenic T-cell lymphoma in a patient with Crohn's disease.

Beigel F, Jürgens M, Tillack C, Subklewe M, Mayr D, Göke B, Brand S, Ochsenkühn T.

Nat Rev Gastroenterol Hepatol. 2009 Jul;6(7):433-6. doi: 10.1038/nrgastro.2009.87. Review.

PMID:
19575026
39.

Severe Legionella pneumophila pneumonia following infliximab therapy in a patient with Crohn's disease.

Beigel F, Jürgens M, Filik L, Bader L, Lück C, Göke B, Ochsenkühn T, Brand S, Seiderer J.

Inflamm Bowel Dis. 2009 Aug;15(8):1240-4. doi: 10.1002/ibd.20866.

PMID:
19217020
40.

The role of the novel Th17 cytokine IL-26 in intestinal inflammation.

Dambacher J, Beigel F, Zitzmann K, De Toni EN, Göke B, Diepolder HM, Auernhammer CJ, Brand S.

Gut. 2009 Sep;58(9):1207-17. doi: 10.1136/gut.2007.130112. Epub 2008 May 15.

PMID:
18483078
41.

The role of interleukin-22 in hepatitis C virus infection.

Dambacher J, Beigel F, Zitzmann K, Heeg MH, Göke B, Diepolder HM, Auernhammer CJ, Brand S.

Cytokine. 2008 Mar;41(3):209-16. doi: 10.1016/j.cyto.2007.11.016. Epub 2008 Jan 11.

PMID:
18191408
42.

Interleukin 31 mediates MAP kinase and STAT1/3 activation in intestinal epithelial cells and its expression is upregulated in inflammatory bowel disease.

Dambacher J, Beigel F, Seiderer J, Haller D, Göke B, Auernhammer CJ, Brand S.

Gut. 2007 Sep;56(9):1257-65. Epub 2007 Apr 20.

43.

IL-22-mediated liver cell regeneration is abrogated by SOCS-1/3 overexpression in vitro.

Brand S, Dambacher J, Beigel F, Zitzmann K, Heeg MH, Weiss TS, Prüfer T, Olszak T, Steib CJ, Storr M, Göke B, Diepolder H, Bilzer M, Thasler WE, Auernhammer CJ.

Am J Physiol Gastrointest Liver Physiol. 2007 Apr;292(4):G1019-28. Epub 2007 Jan 4.

44.

IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration.

Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, Otte JM, Diepolder H, Marquardt A, Jagla W, Popp A, Leclair S, Herrmann K, Seiderer J, Ochsenkühn T, Göke B, Auernhammer CJ, Dambacher J.

Am J Physiol Gastrointest Liver Physiol. 2006 Apr;290(4):G827-38.

45.

Cell differentiation dependent expressed CCR6 mediates ERK-1/2, SAPK/JNK, and Akt signaling resulting in proliferation and migration of colorectal cancer cells.

Brand S, Olszak T, Beigel F, Diebold J, Otte JM, Eichhorst ST, Göke B, Dambacher J.

J Cell Biochem. 2006 Mar 1;97(4):709-23.

PMID:
16215992
46.

CXCR4 and CXCL12 are inversely expressed in colorectal cancer cells and modulate cancer cell migration, invasion and MMP-9 activation.

Brand S, Dambacher J, Beigel F, Olszak T, Diebold J, Otte JM, Göke B, Eichhorst ST.

Exp Cell Res. 2005 Oct 15;310(1):117-30.

PMID:
16125170
47.

IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression.

Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, Otte JM, Diebold J, Diepolder H, Adler B, Auernhammer CJ, Göke B, Dambacher J.

Am J Physiol Gastrointest Liver Physiol. 2005 Nov;289(5):G960-8. Epub 2005 Jul 28.

48.

SOCS-1 inhibits expression of the antiviral proteins 2',5'-OAS and MxA induced by the novel interferon-lambdas IL-28A and IL-29.

Brand S, Zitzmann K, Dambacher J, Beigel F, Olszak T, Vlotides G, Eichhorst ST, Göke B, Diepolder H, Auernhammer CJ.

Biochem Biophys Res Commun. 2005 Jun 3;331(2):543-8.

PMID:
15850793
49.

BRAIN TUMORS IN EARLY INFANCY--PROBABLY CONGENITAL IN ORIGIN.

RASKIND R, BEIGEL F.

J Pediatr. 1964 Nov;65:727-32. No abstract available.

PMID:
14221173
50.

[Function of adrenal cortex in sprue syndrome].

BEIGEL F.

Helv Med Acta. 1958 Jun;25(3):185-207. German. No abstract available.

PMID:
13562739

Supplemental Content

Loading ...
Support Center